首页> 外文期刊>Journal of Endocrinological Investigation: Official Journal of the Italian Society of Endocrinology >Endocrine and neuropsychological assessment in a child with a novel mutation of thyroid hormone receptor: response to 12-month triiodothyroacetic acid (TRIAC) therapy.
【24h】

Endocrine and neuropsychological assessment in a child with a novel mutation of thyroid hormone receptor: response to 12-month triiodothyroacetic acid (TRIAC) therapy.

机译:甲状腺激素受体新突变儿童的内分泌和神经心理学评估:对 12 个月的三碘甲状腺乙酸 (TRIAC) 治疗的反应。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: To determine the endocrine, neuropsychological and genetic features of a child with resistance to thyroid hormone (RTH), and his response to long-term triiodothyroacetic acid (TRIAC) therapy. METHODS: Growth, thyroid function, and neuropsychology were assessed at baseline and during 12-month TRIAC therapy. Genetic analysis was performed by PCR and denaturing high performance liquid chromatography. RESULTS: The main clinical finding was the attention deficit-hyperactivity disorder (ADHD). A novel mutation in exon 10 (phenylalanine to isoleucine in codon 455) was found. Long-term TRIAC therapy was effective in the management of the endocrine and neuropsychological manifestations of the syndrome. CONCLUSIONS: ADHD was the only phenotypic manifestation of this novel mutation of thyroid hormone (TH) receptor. TRIAC is an effective and safe drug in the long-term treatment of children with RTH.
机译:目的:确定甲状腺激素(RTH)耐药儿童的内分泌、神经心理和遗传特征,以及其对长期三碘甲状腺乙酸(TRIAC)治疗的反应。方法: 在基线和 12 个月的 TRIAC 治疗期间评估生长、甲状腺功能和神经心理学。采用PCR和变性高效液相色谱法进行遗传分析。结果:主要临床表现是注意力缺陷多动障碍(ADHD)。在外显子 10 中发现了一种新的突变(密码子 455 中的苯丙氨酸到异亮氨酸)。长期 TRIAC 治疗可有效控制该综合征的内分泌和神经心理表现。结论:ADHD是甲状腺激素(TH)受体这种新型突变的唯一表型表现。TRIAC 是一种有效且安全的药物,用于长期治疗儿童 RTH。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号